vs
AMERICAN AXLE & MANUFACTURING HOLDINGS INC（AXL）とUNITED THERAPEUTICS Corp（UTHR）の財務データ比較。上の社名をクリックして会社を切り替えられます
AMERICAN AXLE & MANUFACTURING HOLDINGS INCの直近四半期売上が大きい（$1.4B vs $790.2M、UNITED THERAPEUTICS Corpの約1.8倍）。UNITED THERAPEUTICS Corpの純利益率が高く（46.1% vs -5.4%、差は51.5%）。UNITED THERAPEUTICS Corpの前年同期比売上増加率が高い（7.4% vs 0.2%）。UNITED THERAPEUTICS Corpの直近四半期フリーキャッシュフローが多い（$173.3M vs $54.7M）。過去8四半期でUNITED THERAPEUTICS Corpの売上複合成長率が高い（8.0% vs -7.2%）
アメリカン・アクスル＆マニュファクチャリング・ホールディングスはミシガン州デトロイトに本社を置くアメリカ企業で、自動車のドライブライン・駆動系部品およびシステムの製造を事業としており、世界中の自動車メーカーに核心部品を供給しています。
ユナイテッド・セラピューティクスは米国のバイオテクノロジー企業で、異種移植を含む臓器移植関連の医薬品や技術を開発しています。主力製品の多くは肺疾患治療や臓器製造分野向けで、メリーランド州とノースカロライナ州に2つの本社を置き、米国各地やカナダにも拠点を構えています。
AXL vs UTHR — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $1.4B | $790.2M |
| 純利益 | $-75.3M | $364.3M |
| 粗利率 | 10.2% | 86.9% |
| 営業利益率 | -2.4% | 45.1% |
| 純利益率 | -5.4% | 46.1% |
| 売上前年比 | 0.2% | 7.4% |
| 純利益前年比 | -449.6% | 20.9% |
| EPS（希薄化後） | $-0.62 | $7.66 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $1.4B | $790.2M | ||
| Q3 25 | $1.5B | $799.5M | ||
| Q2 25 | $1.5B | $798.6M | ||
| Q1 25 | $1.4B | $794.4M | ||
| Q4 24 | $1.4B | $735.9M | ||
| Q3 24 | $1.5B | $748.9M | ||
| Q2 24 | $1.6B | $714.9M | ||
| Q1 24 | $1.6B | $677.7M |
| Q4 25 | $-75.3M | $364.3M | ||
| Q3 25 | $9.2M | $338.7M | ||
| Q2 25 | $39.3M | $309.5M | ||
| Q1 25 | $7.1M | $322.2M | ||
| Q4 24 | $-13.7M | $301.3M | ||
| Q3 24 | $10.0M | $309.1M | ||
| Q2 24 | $18.2M | $278.1M | ||
| Q1 24 | $20.5M | $306.6M |
| Q4 25 | 10.2% | 86.9% | ||
| Q3 25 | 12.6% | 87.4% | ||
| Q2 25 | 13.1% | 89.0% | ||
| Q1 25 | 12.3% | 88.4% | ||
| Q4 24 | 11.2% | 89.7% | ||
| Q3 24 | 11.4% | 88.9% | ||
| Q2 24 | 13.3% | 89.1% | ||
| Q1 24 | 12.4% | 89.2% |
| Q4 25 | -2.4% | 45.1% | ||
| Q3 25 | 3.2% | 48.6% | ||
| Q2 25 | 3.6% | 45.6% | ||
| Q1 25 | 3.0% | 48.2% | ||
| Q4 24 | 2.6% | 48.6% | ||
| Q3 24 | 2.8% | 45.8% | ||
| Q2 24 | 5.3% | 44.7% | ||
| Q1 24 | 4.8% | 52.6% |
| Q4 25 | -5.4% | 46.1% | ||
| Q3 25 | 0.6% | 42.4% | ||
| Q2 25 | 2.6% | 38.8% | ||
| Q1 25 | 0.5% | 40.6% | ||
| Q4 24 | -1.0% | 40.9% | ||
| Q3 24 | 0.7% | 41.3% | ||
| Q2 24 | 1.1% | 38.9% | ||
| Q1 24 | 1.3% | 45.2% |
| Q4 25 | $-0.62 | $7.66 | ||
| Q3 25 | $0.07 | $7.16 | ||
| Q2 25 | $0.32 | $6.41 | ||
| Q1 25 | $0.06 | $6.63 | ||
| Q4 24 | $-0.11 | $6.23 | ||
| Q3 24 | $0.08 | $6.39 | ||
| Q2 24 | $0.15 | $5.85 | ||
| Q1 24 | $0.17 | $6.17 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $708.9M | $2.9B |
| 総負債低いほど良い | $4.0B | — |
| 株主資本純資産 | $640.0M | $7.1B |
| 総資産 | $6.7B | $7.9B |
| 負債/資本比率低いほどレバレッジが低い | 6.31× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $708.9M | $2.9B | ||
| Q3 25 | $714.1M | $2.8B | ||
| Q2 25 | $586.5M | $3.0B | ||
| Q1 25 | $549.2M | $3.3B | ||
| Q4 24 | $552.9M | $3.3B | ||
| Q3 24 | $542.5M | $3.3B | ||
| Q2 24 | $519.9M | $3.0B | ||
| Q1 24 | $469.8M | $2.7B |
| Q4 25 | $4.0B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.6B | — | ||
| Q1 25 | $2.6B | — | ||
| Q4 24 | $2.6B | — | ||
| Q3 24 | $2.6B | — | ||
| Q2 24 | $2.7B | — | ||
| Q1 24 | $2.7B | — |
| Q4 25 | $640.0M | $7.1B | ||
| Q3 25 | $718.4M | $6.6B | ||
| Q2 25 | $673.0M | $7.2B | ||
| Q1 25 | $596.3M | $6.8B | ||
| Q4 24 | $562.8M | $6.4B | ||
| Q3 24 | $616.3M | $6.1B | ||
| Q2 24 | $609.6M | $5.7B | ||
| Q1 24 | $621.4M | $5.3B |
| Q4 25 | $6.7B | $7.9B | ||
| Q3 25 | $5.3B | $7.4B | ||
| Q2 25 | $5.3B | $7.9B | ||
| Q1 25 | $5.1B | $7.7B | ||
| Q4 24 | $5.1B | $7.4B | ||
| Q3 24 | $5.3B | $7.1B | ||
| Q2 24 | $5.3B | $6.7B | ||
| Q1 24 | $5.4B | $6.5B |
| Q4 25 | 6.31× | — | ||
| Q3 25 | 3.61× | — | ||
| Q2 25 | 3.86× | — | ||
| Q1 25 | 4.38× | — | ||
| Q4 24 | 4.58× | — | ||
| Q3 24 | 4.28× | — | ||
| Q2 24 | 4.42× | — | ||
| Q1 24 | 4.40× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $120.5M | $346.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $54.7M | $173.3M |
| FCFマージンFCF / 売上 | 4.0% | 21.9% |
| 設備投資強度設備投資 / 売上 | 4.8% | 21.9% |
| キャッシュ転換率営業CF / 純利益 | — | 0.95× |
| 直近12ヶ月FCF直近4四半期 | $155.1M | $1.0B |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $120.5M | $346.2M | ||
| Q3 25 | $143.3M | $562.1M | ||
| Q2 25 | $91.9M | $191.7M | ||
| Q1 25 | $55.9M | $461.2M | ||
| Q4 24 | $151.2M | $341.2M | ||
| Q3 24 | $143.6M | $377.2M | ||
| Q2 24 | $142.8M | $232.2M | ||
| Q1 24 | $17.8M | $376.5M |
| Q4 25 | $54.7M | $173.3M | ||
| Q3 25 | $79.2M | $351.6M | ||
| Q2 25 | $34.6M | $129.5M | ||
| Q1 25 | $-13.4M | $386.3M | ||
| Q4 24 | $73.2M | $254.5M | ||
| Q3 24 | $70.4M | $300.7M | ||
| Q2 24 | $94.0M | $187.1M | ||
| Q1 24 | $-30.2M | $338.3M |
| Q4 25 | 4.0% | 21.9% | ||
| Q3 25 | 5.3% | 44.0% | ||
| Q2 25 | 2.3% | 16.2% | ||
| Q1 25 | -0.9% | 48.6% | ||
| Q4 24 | 5.3% | 34.6% | ||
| Q3 24 | 4.7% | 40.2% | ||
| Q2 24 | 5.8% | 26.2% | ||
| Q1 24 | -1.9% | 49.9% |
| Q4 25 | 4.8% | 21.9% | ||
| Q3 25 | 4.3% | 26.3% | ||
| Q2 25 | 3.7% | 7.8% | ||
| Q1 25 | 4.9% | 9.4% | ||
| Q4 24 | 5.6% | 11.8% | ||
| Q3 24 | 4.9% | 10.2% | ||
| Q2 24 | 3.0% | 6.3% | ||
| Q1 24 | 3.0% | 5.6% |
| Q4 25 | — | 0.95× | ||
| Q3 25 | 15.58× | 1.66× | ||
| Q2 25 | 2.34× | 0.62× | ||
| Q1 25 | 7.87× | 1.43× | ||
| Q4 24 | — | 1.13× | ||
| Q3 24 | 14.36× | 1.22× | ||
| Q2 24 | 7.85× | 0.83× | ||
| Q1 24 | 0.87× | 1.23× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AXL
| Driveline | $748.4M | 54% |
| Other | $345.7M | 25% |
| Metal Forming | $289.8M | 21% |
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
